{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T13:14:37Z","timestamp":1791983677521,"version":"4.4.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aimed to describe the characteristics, inflammatory markers as surrogates for disease activity, and treatment of patients with polymyalgia rheumatica (PMR) in Japan.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This cohort study analysed the data of 373 patients with PMR retrieved from an electronic medical record database in Japan. Patients were classified into quartiles, based on the daily glucocorticoid (GC) dose over the initial 90\u2009days of treatment (Q1\u2013Q4).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The low GC dose group (Q1) had more patients aged \u226590\u2009years (11.7%) and a higher prevalence of comorbidities. At 52\u2009weeks, GC-free remission was achieved in 10% of patients and higher C-reactive protein levels were observed during the follow-up period. In contrast, the high GC dose group (Q4) exhibited a slower decline in C-reactive protein levels and more events of increased GC dose compared to Q1\u2013Q3. The introduction of methotrexate was low, with 4.3\u20137.3% of patients. The incidence of osteoporosis and diabetes was higher in patients &amp;lt;75\u2009years, whereas the incidence of hypertension was higher in patients \u226575\u2009years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients refractory to high GC doses were identified. Patients receiving inadequately low doses of GCs were older with more comorbidities. This study highlights the unmet medical needs for PMR.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mr\/roaf001","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T10:57:20Z","timestamp":1737111440000},"page":"722-730","source":"Crossref","is-referenced-by-count":4,"title":["Characteristics of patients with polymyalgia rheumatica based on glucocorticoid dose in Japan: A cohort study using routinely collected health data"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health , Japan, Kitakyushu,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Asahi Kasei Pharma Corporation , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Inokuchi","sequence":"additional","affiliation":[{"name":"Real World Evidence Division, Pharmaceutical Business Unit, JMDC Inc. , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Uenaka","sequence":"additional","affiliation":[{"name":"Real World Evidence Division, Pharmaceutical Business Unit, JMDC Inc. , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Fujita","sequence":"additional","affiliation":[{"name":"Real World Evidence Division, Pharmaceutical Business Unit, JMDC Inc. , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Asahi Kasei Pharma Corporation , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"2025072303565662000_R1","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(17)31825-1","article-title":"Polymyalgia rheumatica","volume":"390","author":"Gonz\u00e1lez-Gay","year":"2017","journal-title":"Lancet"},{"key":"2025072303565662000_R2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","article-title":"2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"71","author":"Dasgupta","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2025072303565662000_R3","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.39333","article-title":"2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative","volume":"67","author":"Dejaco","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025072303565662000_R4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00296-017-3874-3","article-title":"Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database","volume":"38","author":"Albrecht","year":"2018","journal-title":"Rheumatol Int"},{"key":"2025072303565662000_R5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/1744666X.2021.1890032","article-title":"Predicting the risk of relapse in polymyalgia rheumatica: novel insights","volume":"17","author":"Prieto-Pe\u00f1a","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"2025072303565662000_R6","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/acr.25216","article-title":"Treatment of polymyalgia rheumatica by rheumatology providers: analysis from the American College of Rheumatology RISE registry","volume":"76","author":"Sattui","year":"2024","journal-title":"Arthritis Care Res"},{"key":"2025072303565662000_R7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105680","article-title":"Glucocorticoid treatment and clinical outcomes in patients with polymyalgia rheumatica: a cohort study using routinely collected health data","volume":"91","author":"Tanaka","year":"2024","journal-title":"Joint Bone Spine"},{"key":"2025072303565662000_R8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/rheumatology\/29.6.456","article-title":"Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis","volume":"29","author":"Dasgupta","year":"1990","journal-title":"Br J Rheumatol"},{"key":"2025072303565662000_R9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/ard.2008.103663","article-title":"Circulating cytokines in active polymyalgia rheumatica","volume":"69","author":"Alvarez-Rodr\u00edguez","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025072303565662000_R10","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/ard-2022-222873","article-title":"Expression of interleukin-6 in synovial tissue of patients with polymyalgia rheumatica","volume":"82","author":"Jiemy","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025072303565662000_R11","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJMoa2303452","article-title":"Sarilumab for relapse of polymyalgia rheumatica during glucocorticoid taper","volume":"389","author":"Spiera","year":"2023","journal-title":"N Engl J Med"},{"key":"2025072303565662000_R12","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1136\/annrheumdis-2021-221126","article-title":"Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2\/3 randomised controlled trial","volume":"81","author":"Bonelli","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025072303565662000_R13","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jama.2022.15459","article-title":"Effect of tocilizumab on disease activity in patients with active polymyalgia rheumatica receiving glucocorticoid therapy: a randomized clinical trial","volume":"328","author":"Devauchelle-Pensec","year":"2022","journal-title":"Jama"},{"key":"2025072303565662000_R14","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.2147\/IJGM.S322111","article-title":"Withdrawal of glucocorticoid therapy is difficult in women with polymyalgia rheumatica: an observational study","volume":"14","author":"Aoki","year":"2021","journal-title":"Int J Gen Med"},{"key":"2025072303565662000_R15","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3899\/jrheum.101149","article-title":"The accuracy of administrative data diagnoses of systemic autoimmune rheumatic diseases","volume":"38","author":"Bernatsky","year":"2011","journal-title":"J Rheumatol"},{"key":"2025072303565662000_R16","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1001\/archinternmed.2009.352","article-title":"Treatment of polymyalgia rheumatica: a systematic review","volume":"169","author":"Hern\u00e1ndez-Rodr\u00edguez","year":"2009","journal-title":"Arch Intern Med"},{"key":"2025072303565662000_R17","first-page":"65","article-title":"Relapse in a population based cohort of patients with polymyalgia rheumatica","volume":"32","author":"Kremers","year":"2005","journal-title":"J Rheumatol"},{"key":"2025072303565662000_R18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","article-title":"Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update","volume":"32","author":"Suzuki","year":"2014","journal-title":"J Bone Miner Metab"},{"key":"2025072303565662000_R19","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025072303565662000_R20","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1757-y","article-title":"Comorbidities in polymyalgia rheumatica: a systematic review","volume":"20","author":"Partington","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025072303565662000_R21","article-title":"Cardiovascular risks associated with gender and aging","volume":"6","author":"Rodgers","year":"2019","journal-title":"J Cardiovasc Dev Dis"},{"key":"2025072303565662000_R22","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40744-018-0112-8","article-title":"Risk associated with cumulative oral glucocorticoid use in patients with giant cell arteritis in real-world databases from the USA and UK","volume":"5","author":"Gale","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2025072303565662000_R23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.semarthrit.2019.12.005","article-title":"Tocilizumab in isolated polymyalgia rheumatica: a systematic literature review","volume":"50","author":"Akiyama","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025072303565662000_R24","article-title":"Kevzara Prescribing Information","author":"FDA","year":"2023"},{"key":"2025072303565662000_R25","article-title":"Package Insert of Prednisolone","author":"Shionogi & Co., Ltd"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf001\/61488493\/roaf001.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/4\/722\/61488493\/roaf001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/35\/4\/722\/61488493\/roaf001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T07:57:04Z","timestamp":1753257424000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/35\/4\/722\/7959583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,1,17]]},"published-print":{"date-parts":[[2025,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf001","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,1,17]]}}}